6919.TW CALIWAY BIOPHARMACEUTICALS CO L

Healthcare Biotechnology Taiwan Stock Exchange
64.00 TWD
Close of Nov 7, 2026
59.90 188.00
Market cap
TWD 99.6B
P/E
-
P/B
10.82x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6919.TW undervalued?

Graham number

The Graham number of CALIWAY BIOPHARMACEUTICALS CO L cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CALIWAY BIOPHARMACEUTICALS CO L fundamental analysis

No fundamental analysis for CALIWAY BIOPHARMACEUTICALS CO L yet.

CALIWAY BIOPHARMACEUTICALS CO L stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CALIWAY BIOPHARMACEUTICALS CO L

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary su…

Full company profile